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Abstract
Background—The association between hepatitis B and metabolic syndrome (MetS) has not
been well described. Overall epidemiologic evidences for this association have suggested
conflicting results. The aim of our study is to determine the association between hepatitis B
infection and MetS using large U.S. population database, the Third National Health and Nutrition
Examination Survey (NHANES III).
Methods—Individuals with age ≥ 18 years were included in this study. MetS was defined
according to NCEP/ATP III guideline. The chronic hepatitis B was defined as presence of
hepatitis B surface antigen. The presence of hepatitis B core antibody with/without surface
antibody, in absence of surface antigen was considered as past exposure to hepatitis B. To
represent national estimates, weighted frequencies for chronic hepatitis B and past exposure to
hepatitis B are reported. Multivariate logistic regression analysis accounting for age, gender, race,
smoking and alcohol status was conducted to identify the independent predictor(s) of MetS.
Results—Our study cohort consisted of population total of 593,594 with chronic hepatitis B and
7,280,620 with past exposure to hepatitis B. Prevalence of MetS among included study cohort was
25.7%. Inverse association was observed between MetS and chronic hepatitis B (aOR: 0.32, 95%
CI 0.12–0.84). Among individual components of MetS, waist circumference was inversely
associated with chronic hepatitis B (aOR: 0.31, 95% CI 0.14–0.71). No significant association
noted between past exposure to hepatitis B and MetS or its individuals components.
Conclusion—In this study, we noted significant inverse association between MetS and chronic
hepatitis B.
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INTRODUCTION
The epidemic of metabolic syndrome (MetS) has been on the rise in conjunction with
increasing prevalence of obesity in the United States. The presence of MetS has also been
shown to be associated with different types of chronic liver diseases, notably nonalcoholic
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fatty liver disease (NAFLD) and hepatitis C infection. The association between NAFLD and
the MetS is well established. NAFLD is part of the spectrum of the MetS and its presence
signifies advanced histology in these patients (1, 2). It is now widely recognized that chronic
hepatitis C (CHC) is associated with insulin resistance and type 2 diabetes (3). Despite the
strong association with MetS among NAFLD and hepatitis C patients, the correlation
between hepatitis B infection and MetS is still elusive.
Some studies have reported association between individual components of MetS and
hepatitis B but others reported the contrary (4, 5). Among individual components,
triglyceride levels have consistently been inversely linked with hepatitis B but association of
other metabolic abnormalities (such as increased waist circumference or diabetes) with
hepatitis B has not been conclusive (6–9).
Considering significant public health burden of hepatitis B with estimated prevalence of
800,000 to 1.4 million along with rising epidemic of MetS in United States, we aim to study
and systemically determine the association between hepatitis B infection, and MetS and its
individual components using a large U.S. population database, the third National Health and
Nutrition Survey (NHANES III).
METHODS
The NHANES III is a survey conducted in the United States from 1988 through 1994 by the
National Center for Health Statistics. The survey consisted of complex, multistage,
stratified, clustered samples of civilian from 2 months age and older to collect information
about their health and nutrition. The NHANES III was approved by the Center for Disease
Control and Prevention’s Institutional Review board. The details of study design and
sampling methods are described elsewhere (10).
Study cohort and definitions
For this study, subjects with age <18 years old, with missing value for hepatitis B core
antibody (Anti-HBc)/hepatitis B surface antigen (HBsAg), with missing values for
individual components of MetS, with chronic hepatitis C (defined as positivity to anti-
HCV), excessive alcohol use with elevated liver enzymes (ALT more than 40 U/l in men
and more than 31 U/l in women, or AST more than 37 U/l in men and more than 31 U/l in
women) and with elevated transferrin level >50% were excluded. After applying these
criteria, our study cohort consisted of population total of 146,158,119 subjects.
Demographic details including age, sex, race, and education level were recorded. Social
history including smoking and alcohol use were included and participants were
appropriately categorized according to their current and past use. Current smoker was
defined as history of ongoing smoking with or without >100 cigarettes in lifetime. Excessive
alcohol consumption was defined as more than 2 drinks per day in men and more than 1
drink per day for women (11). The average alcohol consumption was calculated based on
the responses to 2 survey questions that queried about the number of days of drinking over
the past 12 months and the number of drinks on a given drinking day.
During the physical examination, subject’s body weight, height, and waist to hip ratio were
measured. The body mass index (BMI) was calculated and subjects with BMI ≥30 kg/m2
were considered to be obese. The presence of MetS was determined based on the guidelines
proposed by Third Report of the National Cholesterol Education Program Adult Treatment
Panel (ATP III) (12). The ATP III clinical definition of the MetS requires the presence of 3
or more of the following: (1) waist circumference > 102 cm in men and > 88 cm in women;
(2) a triglyceride level ≥ 150 mg/dl; (3) a high-density lipoprotein (HDL) level < 40 mg/dl in
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men and < 50 mg/dl in women, (4) systolic blood pressure ≥ 130 mm Hg or diastolic
pressure ≥ 85 mm Hg; and (5) fasting plasma glucose ≥ 110 mg/dl. Subjects with MetS were
further stratified into 3 categories depending on the presence of MetS components (3, 4 or 5
metabolic abnormalities).
Laboratory Measurements
The laboratory procedures followed in the NHANES III are described in detail elsewhere
(13). All venous blood samples were immediately centrifuged and shipped weekly at −20 °C
to a central laboratory. Antibodies to hepatitis B core antigen were measured using solid-
phase competitive immunoassay (RIA) while determination of hepatitis B surface antigen
was performed using sandwich radioimmunoassay. Cholesterol and triglycerides were
measured quantitatively by a peroxidase-catalyzed reaction and HDL was measured
following the precipitation of the other lipoproteins. Low-density lipoprotein (LDL) was
calculated by using the formula: LDL = total cholesterol – (triglyceride/5) – HDL. LDL was
not calculated and reported as a missing value if the triglyceride level was > 400 mg/dl.
Definition of chronic hepatitis B infection
Chronic hepatitis B infection was defined as the presence of hepatitis B surface antigen.
Individuals with positive hepatitis B core antibody in absence of surface antigen were
considered to have past exposure to hepatitis B.
Statistical Analysis
Basic descriptive statistics, including weighted frequencies and means, weighted
percentages, and standard error were used to characterize the study population. Appropriate
comparison tests including chi-square test and student t test were used for comparison
between groups for categorical variables and continuous variables respectively.
To represent national estimates, all analyses were conducted using appropriate sample
weight and weighted frequencies are reported to represent cases of chronic hepatitis B, past
exposure to hepatitis B, and controls. Logistic regression including univariate and
multivariate analyses were conducted to identify independent predictors of MetS and its
individual components. We further performed subgroup analysis by ALT level to evaluate
the effects of chronic liver inflammation. ALT level more than 40 U/l in men and more than
31 U/l in women was considered as elevated ALT. Strength of association is reported as
adjusted odds ratio (adjusted for age, sex, race, smoking and alcohol use) with 95%
confidence interval and p value. P-value of less than 0.05 was considered statistically
significant. SAS version 9.2 (SAS institute, Cary, NC) was used for data management and
all statistical analyses.
RESULTS
After inclusion criteria, our study cohort consisted of population total of 593,594 chronic
hepatitis B, 7,280,620 with past exposure to hepatitis B and 138,283,905 controls. The
demographics and characteristics are shown in table 1. When compared to controls, those
with chronic hepatitis B infection were predominantly male (68.1% vs 47.5%, p < 0.001)
and less obese (9.3% vs 21.7%, p = 0.012). They also had a lower non-Hispanic white
population compared to controls (43.1% vs. 78.3%, p <0.001). There were no differences in
the education level, smoking status, and alcohol use. Similarly past exposure to hepatitis B
cohort were largely male (54.1% vs 47.5%, p = 0.011) and had a lower non-Hispanic white
population (44.4% vs. 78.3%, p <0.001), when compared to controls. They also had lower
education level but higher prevalence of smoking.
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Comparison of chronic hepatitis B individuals with controls
The prevalence of MetS was significantly lower in those with chronic hepatitis B infection
compared to controls. (10.4% vs 25.6%, p = 0.019). On multivariate analysis this difference
was also observed to be statistically significant (aOR: 0.32, 95% CI 0.12–0.84). However,
when we considered the relationship between chronic hepatitis B infection and each
individual component of MetS, we found the inverse association between chronic hepatitis B
infection and waist circumference (aOR: 0.31, 95% CI 0.14–0.71). There were also
significant inverse associations noted for chronic hepatitis B with low HDL and impaired
fasting glucose (low HDL - aOR: 0.38, 95% CI 0.15–0.98 and impaired fasting glucose –
aOR: 0.17, 95% CI 0.03–0.97). The stratified analysis by gender showed significant inverse
association between chronic hepatitis B and MetS among male population (aOR: 0.14, 95%
CI 0.04–0.55). (Table 2)
Comparison of past exposure to hepatitis B individuals with controls
The prevalence of MetS in those with previous exposure to hepatitis B was 29.3%, and was
not different than that of controls (25.6%, p = 0.078). We did not observe significant
association in the multivariate analyses after controlling for other covariates (aOR: 0.87,
95% CI 0.69–1.08). There was no significant association noted between past exposure to
hepatitis B status and individual component of MetS. No association noted between past
exposure to hepatitis B, and MetS or its individual components when we analyzed the data
stratified by genders (Table 3).
Subgroup analysis by ALT level
Among subgroup with elevated ALT level, chronic hepatitis B individuals had significantly
low rate of MetS compared to controls (2.1% vs 49.8%, p<0.001). This effect was not
observed for individuals with past exposure to hepatitis B. Prevalence of MetS was 42.4%
among individuals with past exposure to hepatitis B compared to 49.8% in controls
(p=0.583).
Though difference in prevalence of MetS was not statistically significant among individuals
with chronic hepatitis B (12.5%) and controls (24.5%) with normal ALT levels (p=0.051),
definite trend was noted towards lower rate in chronic hepatitis B group. Difference in rate
of MetS was not significantly different for past exposure to hepatitis B and controls with
normal ALT levels.
Additional comparison analyses between individuals with chronic hepatitis B and past
exposure to hepatitis B were conducted. Individuals with chronic hepatitis B had lower
prevalence of metabolic syndrome (aOR: 0.35, 95% CI 0.13–0.97). Among individual
components, waist circumference and low HDL and impaired fasting glucose were inversely
associated with chronic hepatitis B in reference to past exposure to hepatitis B (Table 4).
DISCUSSION
HBV is a hepatotrophic virus that causes acute and chronic infection. At the molecular level,
HBV X protein (HBx), 1 of 4 open reading frames in the HBV genome, has been implicated
in regulating apoptosis, inflammation, and tumorigenesis (14, 15). Recent studies
demonstrated that HBx causes hepatic steatosis through the transcriptional activation of
sterol regulatory element-binding protein 1 (SREBP1) and peroxisome proliferator-activated
receptor (PPARγ) transcripts(16), suggesting the involvement of HBx in the transcriptional
regulation of lipid and glucose metabolism-related genes. Based on the molecular
mechanism, it is plausible to hypothesize the relationship between chronic hepatitis B
infection and the presence of MetS. In this large population based study, we systemically
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examined the association between metabolic syndrome, and chronic hepatitis B and past
exposure to hepatitis B. Our study results showed inverse association between MetS and
chronic hepatitis B. However, when each component of MetS was analyzed, chronic
hepatitis B infectivity was inversely association with waist circumference, low HDL and
impaired fasting glucose. Our study results are consistent with previous study by Jan CF et
al, which also suggested inverse association between MetS and chronic hepatitis B (4).
The mechanism underlying the inverse association between low HDL levels and chronic
hepatitis B infection is unclear. However, it is plausible that chronic inflammatory cytokines
which were found to be increased in subjects with chronic hepatitis B infection might play a
role. The evidence suggests that changes in the adipokines in chronic hepatitis B individuals
might be responsible for such derangements in lipid levels (17, 18). Similar observations
regarding association between chronic hepatitis B and low HDL was reported in previous
study. Higher level of HBV DNA levels were associated with lower HDL level (19). Due to
lack of HBV DNA levels in our database, we were not able to perform such subgroup
analysis. Likewise, it is still unclear on why chronic hepatitis B is inversely associated with
impaired fasting glucose. Some studies have suggested association between hepatitis B and
hyperglycemia while others refute this association (7, 8, 20). Our subgroup analysis by ALT
level suggested significantly low rate of MetS among individuals with chronic hepatitis B in
presence of elevated ALT level. This may suggest possible role of chronic liver
inflammation leading to derangements in glucose and lipid levels. Cirrhosis might be
responsible for development of such metabolic derangements rather than virus itself among
individuals with chronic hepatitis B (21). Unfortunately we were not able perform subgroup
analysis by cirrhosis status as NHANES III database does not provide histological data.
Mechanistic or prospective studies are needed to verify these findings.
The strength of our study is the large sample size in NHANES III dataset and the study
design allows the results to be extrapolated to the entire U.S. population. By using weighted
statistical analysis we were able to demonstrate association of MetS among estimated
593,594 chronic hepatitis B individuals in U.S. population. Sample weights also allowed us
to adjust for selection probabilities. However, our study has some shortcomings. First, the
cross sectional study design did not allow us to examine the temporal association between
chronic hepatitis B infectivity, and MetS and its individual components. Second, we do not
have the data on HBV DNA levels or adipokines to further explore the metabolic outcomes
of interest in different subgroups. Third, lack of liver histology data did not allow us to
perform subgroup analysis by cirrhosis status.
In this large U.S. population database, we found significant inverse association between
MetS and chronic hepatitis B. Among individual components of MetS, waist circumference,
low HDL and impaired fasting glucose were inversely associated with chronic hepatitis B.
We did not find significant association between past exposure to hepatitis B and MetS.
Further well designed, longitudinal follow-up studies are required to confirm this
associations between viral hepatitis B, and MetS and its individual components.
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Treatment Panel
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Table 1
Baseline characteristics of study cohort
Chronic hepatitis B Weighted %
(S.E.)
Past exposure to hepatitis B
Weighted % (S.E.)
Controls Weighted % (S.E.)
Age (in years) 40.9 (2.2) 48.9 (1.1) 42.9 (0.4)
Sex
 Male 68.1 (3.8) 54.1 (2.5) 47.5 (0.5)
 Female 31.9 (3.8) 45.9 (2.5) 52.5 (0.5)
Race
 Non-Hispanic white 43.1 (9.9) 44.4 (3.2) 78.3 (1.2)
 Others 56.9 (9.9) 55.6 (3.2) 21.7 (1.2)
Education
 Less than high school 18.6 (4.4) 40.0 (3.0) 23.6 (1.1)
 High School 35.2 (7.1) 27.2 (2.4) 34.3 (0.9)
 More than high school 46.2 (9.9) 32.8 (2.8) 42.1 (1.4)
Current smoker
 Yes 19.8 (4.5) 31.3 (2.2) 26.6 (0.9)
 No 80.2 (4.5) 68.7 (2.2) 73.4 (0.9)
Heavy alcohol use
 Yes 4.2 (1.1) 6.6 (1.2) 7.2 (0.5)
 No 95.8 (1.1) 93.4 (1.2) 92.8 (0.5)
BMI
 ≤ 24.9 68.0 (5.0) 46.6 (3.2) 46.6 (1.0)
 25–29.9 22.7 (4.2) 32.4 (3.0) 31.7 (0.5)
 ≥30 9.3 (2.0) 21.0 (2.0) 21.7 (0.8)
AST level (U/L) 34.0 (5.7) 21.2 (0.4) 20.5 (0.1)
ALT level (U/L) 37.0 (10.1) 16.8 (0.7) 16.8 (0.4)
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Table 4
Odds ratio of the metabolic syndrome and its individual components in chronic hepatitis B individuals
compared to past exposure to hepatitis B
Total
Crude OR (95% CI) Adjusted OR* (95% CI)
Metabolic syndrome
0.28 0.35
0.10–0.76 0.13–0.97
High BP
0.46 0.66
0.22–0.95 0.29–1.54
Waist circumference
0.31 0.41
0.13–0.78 0.17–0.96
High Triglyceride
0.40 0.45
0.14–1.16 0.15–1.38
Low HDL
0.35 0.39
0.15–0.85 0.16–0.97
Impaired fasting glucose
0.11 0.12
0.01–0.87 0.02–0.80
*Adjusted for age, sex, race, smoking and alcohol status
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